Moderna

Moderna, Inc., headquartered in Cambridge, Massachusetts, is an ultra-innovative biotechnology company that pioneered the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Founded in 2010, Moderna’s core premise is that mRNA can serve as the ‘software of life,’ allowing scientists to program a patient’s own cells to produce therapeutic proteins or viral antigens to prevent or treat disease. The company spent a decade quietly perfecting the underlying technology, particularly the complex lipid nanoparticle (LNP) delivery systems required to safely transport mRNA into human cells.

This foundational work culminated in an unprecedented global achievement during the COVID-19 pandemic when Moderna, in partnership with the NIH, designed, manufactured, and secured authorization for its highly effective Spikevax vaccine in less than a year. Beyond COVID-19, Moderna boasts an expansive and highly diversified clinical pipeline spanning infectious disease vaccines (including RSV, CMV, and Influenza), immuno-oncology, rare diseases, and autoimmune disorders.

In oncology, they are making groundbreaking strides in individualized neoantigen therapy (INT), partnering with major pharma to create custom mRNA cancer vaccines tailored to the specific genetic mutations of an individual patient’s tumor. Moderna operates a massive, fully digital and highly automated manufacturing facility in Norwood, Massachusetts, and is rapidly expanding its production footprint globally to support its ambitious pipeline.

Characterized by a relentless drive for innovation, a purely digital-first operational mindset, and massive capital reserves, Moderna is fundamentally reshaping the future of preventative and therapeutic medicine.